Colorectal cancer (CRC) is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. It is the third leading cause of death from cancer in the United States.
According to the American Cancer Society, colorectal cancer is cancer that starts in the colon or the rectum; these cancers can also be named colon cancer or rectal cancer, depending on where they start. Also, most colorectal cancers (CRCs) start as a growth on the inner lining of the colon or rectum; these growths are called polyps. While the most common site of metastases, for colon or rectal cancer, is the liver, CRC cells may also spread to the lungs, bones, brain or spinal cord. Besides, mCRC is different from recurrent colorectal cancer.
Get FREE sample copy at:
The Metastatic Colorectal Cancer market report also covers emerging drugs, current treatment practices, Metastatic Colorectal Cancer market share of the individual therapies, current and forecasted Metastatic Colorectal Cancer Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Metastatic Colorectal Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Metastatic Colorectal Cancer Market Key Facts
According to the GLOBOCAN 2018 data, cancer of the colon has the fourth-highest incidence in the world, while cancer of the rectum is the eighth position. Together, CRCs are the third most commonly diagnosed form of cancer globally, comprising 11% of all cancer diagnoses.
As per the American Institute for Cancer Research, there were over 1.8 million new cases in 2018 worldwide. In 2018, the age-standardised rate of CRC per 100,000 cases were 38.9 in Japan, 33.4 in Spain and 32.1 in the United Kingdom.
- As per a study conducted by Vuik et al. titled “Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years,” for both sexes combined, CRC incidence increased to 7.9%/year between 2004 and 2016 in the age group of 20–29. However, in the age group of 30–39, the CRC incidence became 6.8% annually between 2005 and 2016 (from 2.8–6.4 cases/100 000 persons between 2006 and 2016) and 1.6% annually in the age group 40–49.
Approximately 21% of people newly diagnosed with CRC have distant metastatic disease at the time of diagnosis.
Key Benefits of Metastatic Colorectal Cancer Market Report
Metastatic Colorectal Cancer market report provides an in-depth analysis of Metastatic Colorectal Cancer Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Metastatic Colorectal Cancer market report will help in developing business strategies by understanding the Metastatic Colorectal Cancer Market trends & developments, key players, and future market competition that will shape and drive the Metastatic Colorectal Cancer market in the upcoming years.
The Metastatic Colorectal Cancer market report covers Metastatic Colorectal Cancer current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Metastatic Colorectal Cancer market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Metastatic Colorectal Cancer market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Metastatic Colorectal Cancer market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Metastatic Colorectal Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Metastatic Colorectal Cancer Epidemiology
The Metastatic Colorectal Cancer epidemiology section covers insights about the historical and current Metastatic Colorectal Cancer patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Metastatic Colorectal Cancer Drugs Uptake and Key Market Players
The Metastatic Colorectal Cancer Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Colorectal Cancer market or expected to get launched in the market during the study period. The analysis covers Metastatic Colorectal Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The Metastatic Colorectal Cancer (mCRC) market size is expected to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage.
Metastatic Colorectal Cancer Companies:
Merck Sharp and Dohme
And many others.
Metastatic Colorectal Cancer Therapies covered in the report include:
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Metastatic Colorectal Cancer Competitive Intelligence Analysis
4. Metastatic Colorectal Cancer Market Overview at a Glance
5. Metastatic Colorectal Cancer Disease Background and Overview
6. Metastatic Colorectal Cancer Patient Journey
7. Metastatic Colorectal Cancer Epidemiology and Patient Population
8. Metastatic Colorectal Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Colorectal Cancer Unmet Needs
10. Key Endpoints of Metastatic Colorectal Cancer Treatment
11. Metastatic Colorectal Cancer Marketed Products
12. Metastatic Colorectal Cancer Emerging Therapies
13. Metastatic Colorectal Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Colorectal Cancer Market Outlook (7 major markets)
16. Metastatic Colorectal Cancer Access and Reimbursement Overview
17. KOL Views on the Metastatic Colorectal Cancer Market.
18. Metastatic Colorectal Cancer Market Drivers
19. Metastatic Colorectal Cancer Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Related Reports By DelveInsight
Metastatic Colorectal Cancer Epidemiology Forecast
DelveInsight’s Metastatic Colorectal Cancer – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of the Metastatic Colorectal Cancer in the 7MM.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States